A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Autor: Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
Rok vydání: 2022
Předmět:
Zdroj: Leukemialymphoma.
ISSN: 1029-2403
Databáze: OpenAIRE